Sign In
Buy CLLS
$3.09
-0.290 (-8.58%)
At Close: Jun 03, 2026
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 29, 2020
08:30pm, Monday, 29'th Jun 2020
NEW YORK, June 29, 2020 -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 29, 2020 at its head office in Paris,.
Cellectis Starting To Look Like A Biotech Buy
01:35pm, Monday, 29'th Jun 2020
Cellectis has shown promise in its oncology treatment and a new paper shows that it's able to overcome early risk detection. A new chief medical officer signing
Cellectis Published Streamlined Manufacturing Method to Generate Ultrapure Allogeneic CAR T-Cell Therapies
08:30pm, Thursday, 25'th Jun 2020
NEW YORK, June 25, 2020 -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic.
Monthly information on share capital and company voting rights
08:30pm, Wednesday, 10'th Jun 2020
NEW YORK, June 10, 2020 -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting.
Moving Average Crossover Alert: Cellectis
01:05pm, Monday, 08'th Jun 2020
Cellectis S.A. (CLLS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Is Cellectis (CLLS) Outperforming Other Medical Stocks This Year?
03:30pm, Wednesday, 03'rd Jun 2020
Is (CLLS) Outperforming Other Medical Stocks This Year?
Cellectis' Shares March Higher, Can It Continue?
11:56am, Monday, 01'st Jun 2020
As of late, it has definitely been a great time to be an investor in Cellectis.
Cellectis Appoints Biopharma Veteran Leopold Bertea as Senior Vice President of Technical Operations - Europe
08:30pm, Monday, 18'th May 2020
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced
How Cellectis (CLLS) Stock Stands Out in a Strong Industry
01:08pm, Wednesday, 13'th May 2020
Cellectis (CLLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for May 12th
02:02pm, Tuesday, 12'th May 2020
Top Ranked Momentum Stocks to Buy for May 12th
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 29, 2020
08:30pm, Monday, 11'th May 2020
In the context of the COVID-19 epidemic and in accordance with Ordinance No. 2020-321 of March 25, 2020, the annual general meeting will take place on June 29, 2020 at 9 AM CET at Cellectis’ headqua
Cellectis SA (CLLS) Q1 2020 Earnings Call Transcript
06:00pm, Saturday, 09'th May 2020
CLLS earnings call for the period ending March 31, 2020.
Cellectis S.A. (EPA:ALCLS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
10:00am, Friday, 08'th May 2020
Cellectis S.A. (EPA:ALCLS) just released its quarterly report and things are looking bullish. The results were...
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2020
08:30pm, Wednesday, 06'th May 2020
Proprietary allogeneic CAR T-cell programs on track in Phase 1 dose escalation trials; AMELI-01 in r/r AML patients, BALLI-01 in r/r B-ALL patients and MELANI-01 in r/r MM.
Gilead, Takeda Rumored to Have Sights on Iovance
10:13pm, Thursday, 30'th Apr 2020
Potential suitors looking to expand their work in cancer likely covet company's technology Continue reading...
